Monopar Therapeutics Inc. Common Stock (MNPR) is a publicly traded Healthcare sector company. As of May 20, 2026, MNPR trades at $57.95 with a market cap of $376.82M and a P/E ratio of -29.81. MNPR moved -1.64% today. Year to date, MNPR is -16.38%; over the trailing twelve months it is +49.59%. Its 52-week range spans $4.50 to $105.00. Analyst consensus is strong buy with an average price target of $113.00. Rallies surfaces MNPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ALXN1840 Phase 2 Trial in Nine Patients Cuts Copper Balance 6.08 mg, Boosts Fecal Excretion 50%: Monopar's Phase 2 trial of ALXN1840 in nine Wilson disease patients showed a cumulative decrease in copper balance of 6.08 mg over 21 days (95% CI -10.18 to -1.98 mg) with mean reduction of 0.37 mg (p=0.005). The treatment raised the fecal copper output-to-intake ratio by 50% (p=0.041) and had no serious adverse events.
| Metric | Value |
|---|---|
| Price | $57.95 |
| Market Cap | $376.82M |
| P/E Ratio | -29.81 |
| EPS | $-1.85 |
| Dividend Yield | 0.00% |
| 52-Week High | $105.00 |
| 52-Week Low | $4.50 |
| Volume | 235.59K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-13.72M |
| Gross Margin | 0.00% |
7 analysts cover MNPR: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $113.00.